Zobrazeno 1 - 10 of 33 pro vyhledávání: '"J J V McMurray"'
1
Efficacy of Pulmonary Artery Pressure Monitoring in Patients with Chronic Heart Failure: A Meta-Analysis of Three Randomized Controlled Trials
Autor: P R D Clephas, S P Radhoe, E Boersma, J Gregson, P S Jhund, W T Abraham, J J V McMurray, R A de Boer, J J Brugts
Publikováno v: European Heart Journal.
Background and Aims Adjustment of treatment based on remote monitoring of pulmonary artery (PA) pressure may reduce the risk of hospital admission for heart failure (HF). We have conducted a meta-analysis of large randomized trials investigating this
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8720a9b4cae0aa2ddd9bc872a5287350
https://doi.org/10.1093/eurheartj/ehad346
Zobrazit plný text záznamu
2
Implications of the 2021 CKD-EPI cystatin C/creatinine eGFR equation for eligibility for therapy in HFrEF: insights from PARADIGM-HF
Autor: P Tolomeo, T Kondo, J H Butt, A S Desai, M P Lefkowitz, J L Rouleau, S D Solomon, K Swedberg, M R Zile, G Campo, P S Jhund, M Packer, J J V McMurray
Publikováno v: European Heart Journal. 43
Background Estimated glomerular filtration rate (eGFR) is a key determinant of eligibility for many life-saving therapies in HFrEF. Recently, the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) provided new equations based on creatinine (
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::aa6183052e8a4034d52ca2a50113697a
https://doi.org/10.1093/eurheartj/ehac544.843
Zobrazit plný text záznamu
3
Alkaline phosphatase and bilirubin combined are a powerful predictor of outcome in patients with heart failure and reduced ejection fraction: an analysis of the ATMOSPHERE and PARADIGM-HF trials
Autor: C Adamson, J H Butt, J Rouleau, W Abraham, A Desai, K Dickstein, L Kober, M P Lefkowitz, M Packer, M C Petrie, K Swedberg, S D Solomon, M Zile, P S Jhund, J J V McMurray
Publikováno v: European Heart Journal. 43
Introduction Bilirubin is a recognized predictor of adverse outcomes in patients with heart failure and reduced ejection fraction (HFrEF), possibly because it is a marker of congestion. Alkaline phosphatase (ALP) is an enzyme produced in many tissues
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::29b89667cdfbed618bdd6362312b9a7c
https://doi.org/10.1093/eurheartj/ehac544.871
Zobrazit plný text záznamu
4
Relationship between endothelin-1, heart failure with reduced ejection fraction and dapagliflozin: findings from DAPA-HF
Autor: S E Yeoh, K F Docherty, P S Jhund, A Hammarstedt, S E Inzucchi, L Kober, M N Kosiborod, F A Martinez, P Ponikowski, S D Solomon, N Sattar, P Welsh, M S Sabatine, D A Morrow, J J V McMurray
Publikováno v: European Heart Journal. 43
Background Circulating Endothelin-1 (ET-1) is associated with heart failure (HF) severity and has also been widely implicated in the pathophysiology of renal disease. However, its prognostic importance and relationship with kidney function in patient
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b77df0405a7d9278ae950476346dddfd
https://doi.org/10.1093/eurheartj/ehac544.833
Zobrazit plný text záznamu
5
A comprehensive study of the incremental prognostic value of novel biomarkers in PARADIGM-HF (Bio-PREDICT-HF)
Autor: K McDowell, J Simpson, P S Jhund, W T Abraham, B Claggett, J Cunningham, A S Desai, L Kober, M Prescott, J L Rouleau, K Swedberg, M R Zile, S D Solomon, M Packer, J J V McMurray
Publikováno v: European Heart Journal. 43
Background Although multiple novel biomarkers have individually been shown to predict outcomes in patients with HFrEF, the value of these over and above conventional clinical and laboratory variables, plus natriuretic peptides, is uncertain. Purpose
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a82941e29f51d2c4025bc08c048e8398
https://doi.org/10.1093/eurheartj/ehac544.914
Zobrazit plný text záznamu
6
Efficacy and safety of sacubitril/valsartan according to frailty in heart failure with preserved ejection fraction: a post hoc analysis of the PARAGON-HF trial
Autor: J H Butt, P Dewan, L Kober, P S Jhund, S D Solomon, J J V McMurray
Publikováno v: European Heart Journal. 43
Introduction Frailty is an increasingly common problem and frail patients are less likely to receive pharmacological therapy because the benefit/risk profile is perceived to be less favorable than in non-frail patients. Purpose We investigated the pr
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::31643f91c3bbc956f0fa6ea9ac01f109
https://doi.org/10.1093/eurheartj/ehac544.1052
Zobrazit plný text záznamu
7
Outcomes related to IGFBP-7 in patients with heart failure and reduced ejection fraction and effects of dapagliflozin: findings from DAPA-HF
Autor: C Adamson, P Welsh, D A Morrow, K F Docherty, A Hammarstedt, S E Inzucchi, L Kober, M N Kosiborod, F A Martinez, P Ponikowski, M S Sabatine, S D Solomon, N Sattar, P S Jhund, J J V McMurray
Publikováno v: European Heart Journal. 43
Introduction Insulin-like growth factor binding protein 7 (IGFBP-7) has been proposed as a novel prognostic biomarker in heart failure, but the association between IGFBP-7 and cardiovascular outcomes has not been examined in a large cohort of patient
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::847ef539a6d97b2bcfcdcfa96eb17812
https://doi.org/10.1093/eurheartj/ehac544.913
Zobrazit plný text záznamu
8
Differing approaches to analyse on-treatment cardiovascular events comparing daprodustat with darbepoetin: results from the ASCEND-ND trial
Autor: F McCausland, A Singh, B Claggett, K Carroll, J Wittes, J J V McMurray, V Perkovic, S Snappin, R Lopes, S Solomon
Publikováno v: European Heart Journal. 43
Background Hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) represent a potential new therapeutic option to treat anaemia of chronic kidney disease (CKD). Purpose In the recent ASCEND-ND trial (NCT02876835)1, conducted in patients wi
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::da205521ad2e482ae87db6de4173f407
https://doi.org/10.1093/eurheartj/ehac544.2621
Zobrazit plný text záznamu
9
Causes of death in patients with chronic kidney disease: insights from the ASCEND-D and ASCEND-ND cardiovascular outcomes trials
Autor: A K Singh, A Acharya, K Carroll, R D Lopes, F R McCausland, L Mulloy, V Perkovic, S Solomon, S S Waikar, C Wanner, M G Wong, A R Cobitz, S A Mallett, B C Shaddinger, J J V McMurray
Publikováno v: European Heart Journal. 43
Background There are limited contemporary data available regarding adjudicated causes of death in patients with chronic kidney disease (CKD). Prior studies have indicated that cardiovascular (CV) events are one of the most common causes of death amon
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::24edb70151341052045d6ff69eeea67f
https://doi.org/10.1093/eurheartj/ehac544.1053
Zobrazit plný text záznamu
10
Long-term cardiovascular outcomes in five-year cancer survivors: a nationwide cohort study
Autor: G Sun, M Petrie, N N Lang, J J V McMurray, P S Jhund, L L Cheng, M Schou, C Torp-Pedersen, E L Fosboel, L Koeber, J H Butt
Publikováno v: European Heart Journal. 43
Background Patients with cancer have higher short-term rates of cardiovascular events than the general population. However, little is known about rates of long-term cardiovascular outcomes in 5-year cancer survivors, especially in older patients. Obj
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5afa466e59c8727a0801fb0b9489d45f
https://doi.org/10.1093/eurheartj/ehac544.2568
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje